Tatjana Huebner
Overview
Explore the profile of Tatjana Huebner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
6
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atemnkeng Ntam V, Huebner T, Steffens M, Roethlein C, Haenisch B, Stingl J, et al.
PLoS One
. 2024 Oct;
19(10):e0311267.
PMID: 39388460
Background: Pharmacogenetic testing in routine care could provide benefits for patients, doctors and statutory health insurances. Therefore, the aim of the retrospective, observational study Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit...
2.
Huebner T, Steffens M, Scholl C
Mol Biol Rep
. 2023 Oct;
50(11):9587-9599.
PMID: 37787843
Background: Analytical validity is a prerequisite to use a next generation sequencing (NGS)-based application as an in vitro diagnostic test or a companion diagnostic in clinical practice. Currently, in the...
3.
Fracowiak J, Huebner T, Hess S, Roethlein C, Langner D, Schneider U, et al.
Pharmacogenomics J
. 2022 Feb;
22(2):136-144.
PMID: 35102241
The impact of genetic variability of pharmacogenes as a possible risk factor for adverse drug reactions is elucidated in the EMPAR (Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung/English:...
4.
Huebner T, Steffens M, Scholl C
Mol Diagn Ther
. 2021 Dec;
26(1):89-103.
PMID: 34905151
On the basis of scientific evidence, information on the option, recommendation or requirement to test for pharmacogenetic or pharmacogenomic biomarkers is incorporated in the Summary of Product Characteristics of an...
5.
Huebner T, Scholl C, Steffens M
Diagnostics (Basel)
. 2021 Jul;
11(7).
PMID: 34206978
For many authorized drugs, accumulating scientific evidence supports testing for predictive biomarkers to apply personalized therapy and support preventive measures regarding adverse drug reactions and treatment failure. Here, we review...
6.
Huebner T, Steffens M, Linder R, Fracowiak J, Langner D, Garling M, et al.
BMJ Open
. 2020 Apr;
10(4):e032624.
PMID: 32345696
Introduction: Pre-emptive testing of pharmacogenetically relevant single-nucleotide polymorphisms can be an effective tool in the prevention of adverse drug reactions and therapy resistance. However, most of the tests are not...